Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | TYMS | P04818 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | STAT6 | P42226 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.35 |
| ▸ | S100A4 | P26447 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7162505 | 0.93 | TYMS (0.53) | ALDH1A1MAPTTYMSMAPK1PKM | |
| SCHEMBL25276892 | 0.90 | MAPT (0.49) | ALDH1A1MAPTTYMSMAPK1PKM | |
| Ethylene SCHEMBL7162329 | 0.90 | TYMS (0.51) | ALDH1A1MAPTTYMSMAPK1PKM | |
| SCHEMBL30997742 | 0.81 | ALDH1A1 (0.61) | ALDH1A1MAPTTYMSMAPK1PKM | |
| SCHEMBL22028064 | 0.81 | ALDH1A1 (0.61) | ALDH1A1MAPTTYMSMAPK1PKM | |
| SCHEMBL1994756 | 0.79 | MAPT (0.45) | ALDH1A1MAPTTYMSBAZ1AHSD17B10 | |
| SCHEMBL6204798 | 0.79 | MAPK1 (0.42) | ALDH1A1MAPTMAPK1BAZ1AHSD17B10 | |
| SCHEMBL7894568 | 0.79 | ATM (0.42) | ALDH1A1MAPTMAPK1BAZ1AHSD17B10 | |
| SCHEMBL11980460 | 0.79 | BAZ1A (0.37) | ALDH1A1MAPTTYMSMAPK1BAZ1A | |
| SCHEMBL1025369 | 0.79 | ALDH1A1 (0.40) | ALDH1A1MAPTMAPK1PKMBAZ1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583738-B1 | INDENONCARBOXYLIC ACIDS DERIVATIVES AND THEIR USE FOR THE TREATMENT OF AND PREVENTING DIABETES AND DYSLIPIDAEMIA | MERCK PATENT GMBH (DE) | 2017-05-10 | — | — | EP | claimed |
| JP-4762551-B2 | — | — | 2011-08-31 | — | — | JP | claimed |
| US-20060111445-A1 | Novel carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia | MERCK PATENT GMBH (DE) | 2006-05-25 | — | — | US | claimed |
| EP-1583738-A1 | INDENONCARBOXYLIC ACIDS DERIVATIVES AND THEIR USE FOR THE TREATMENT OF AND PREVENTING DIABETES AND DYSLIPIDAEMIA | MERCK PATENT GmbH (DE) | 2005-10-12 | — | — | EP | claimed |
| WO-2004063148-A1 | INDENONCARBOXYLIC ACIDS DERIVATIVES AND THEIR USE FOR THE TREATMENT OF AND PREVENTING DIABETES AND DYSLIPIDAEMIA | MERCK PATENT GMBH (DE) | 2004-07-29 | — | — | WO | claimed |
| WO-2022121805-A1 | FUSED RING COMPOUND AS NAV1.8 INHIBITOR AND USE THEREOF | 成都康弘药业集团股份有限公司 | 2022-06-16 | — | — | WO | disclosed |
| CN-114591293-A | Fused ring compound as Nav1.8 inhibitor and application thereof | 成都康弘药业集团股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-109956928-B | Pyridine compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-07-09 | — | — | CN | disclosed |
| CN-109071498-B | Kinase inhibitor and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-110655503-A | Substituted triazole compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2020-01-07 | — | — | CN | disclosed |
| US-10189826-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-22 | — | — | US | disclosed |
| US-20090075996-A1 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2009-03-19 | — | — | US | disclosed |
| US-7482484-B2 | Carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia | MERCK PATENT GMBH (DE) | 2009-01-27 | — | — | US | disclosed |
| CN-101213190-A | Compounds and compositions useful as TPO mimetics | IRM LLC (BM) | 2008-07-02 | — | — | CN | disclosed |
| EP-1910338-A2 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM, LLC (BM) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007009120-A2 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2007-01-18 | — | — | WO | disclosed |
| US-20060111445-A1 | Novel carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia | MERCK PATENT GMBH (DE) | 2006-05-25 | — | — | US | disclosed |
| EP-1583738-A1 | INDENONCARBOXYLIC ACIDS DERIVATIVES AND THEIR USE FOR THE TREATMENT OF AND PREVENTING DIABETES AND DYSLIPIDAEMIA | MERCK PATENT GmbH (DE) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004063148-A1 | INDENONCARBOXYLIC ACIDS DERIVATIVES AND THEIR USE FOR THE TREATMENT OF AND PREVENTING DIABETES AND DYSLIPIDAEMIA | MERCK PATENT GMBH (DE) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111445-A1 | Novel carboxylic acids and derivatives for the treatment of and preventing diabetes and dyslipidaemia | NR1H3, LDLR, NR1H2 | ALDH1A1 2283/4885MAPT 4833/4885TYMS 3338/4885 |
| US-20090075996-A1 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | MPL, TPO, THPO | ALDH1A1 1941/4885MAPT 4215/4885TYMS 179/4885 |
| US-10189826-B2 | Heterocyclic compounds and methods of use | HRAS, VHL, ESRRB | ALDH1A1 2384/4885MAPT 4672/4885TYMS 1027/4885 |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | HRAS, VHL, ESRRB | ALDH1A1 2384/4885MAPT 4672/4885TYMS 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.